NCT07139106View on ClinicalTrials.gov

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

Ketamine hydrochloride infusion

single racemic ketamine hydrochloride 0.5 mg/kg infusion

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

American Foundation for Suicide Prevention

OTHER

lead

New York State Psychiatric Institute

OTHER